Document:

Exhibit 10.1

 

	
         

        CHAIRMAN AGREEMENT

         

  

ALI KHARAZMI

 

and

 

NUGENE INTERNATIONAL, INC.

 

22 September, 2016

 

     

     

    

 

	CHAIRMAN AGREEMENT

 

I

PARTIES

 

THIS CHAIRMAN AGREEMENT
(the “Agreement”) is entered into effective as of the 22nd day of September, 2016 (the “Effective
Date”), by and between ALI KHARAZMI, a California corporation (“Kharazmi”); and, NUGENE
INTERNATIONAL, INC., a Nevada corporation (“NuGene”). Kharazmi and NuGene are sometimes referred to collectively
herein as the “Parties”, and each individually as a “Party”.

 

II

RECITALS

 

A.           NuGene
desires assurance of the continued association and services of Kharazmi in order to retain his experience, skills, abilities, background,
and knowledge, and it desires to continue to have Kharazmi serve as the Chairman of NuGene’s Board of Directors (the “Board”)
on the terms and conditions set forth herein.

 

B.           Kharazmi
desires to continue to serve as the Chairman of the Board of NuGene, and is willing to accept such continued service on the terms
and conditions set forth in this Agreement.

 

C.           NuGene
and Kharazmi desire to, among other things, provide for benefits payable to Kharazmi upon certain events and reflect the application
of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), to the benefits that may
be provided to Kharazmi hereunder..

 

D.           NOW,
THEREFORE, in consideration of the promises and the mutual covenants contained herein, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:

 

III

APPOINTMENT

 

3.1          Position
and Duties. NuGene hereby appoints Kharazmi to serve as the Chairman of the Board. As the Chairman, Kharazmi shall do and
perform all services, acts, or things necessary or advisable to manage and conduct the business of the Board and which are normally
associated with the position of chairman of the board of a similarly situated public company, consistent with the Bylaws of NuGene
and as required by the Board. As Chairman of the Board, Kharazmi shall, among other things, lead all meetings of the Board and
all meetings of the stockholders of NuGene, as well as set the agenda for all meetings of the Board and the stockholders.

 

3.2          Policies
and Practices. The appointment of Kharazmi hereunder shall be further governed by the policies and practices established
from time to time by the Board. In the event of any inconsistencies or conflict between this Agreement and such policies and practices,
the terms and conditions of this Agreement shall control.

 

3.3          Location. Kharazmi
will attend and participate in meetings via teleconference, videoconference, or in person, and will consult with other members
of the Board regularly and as necessary via telephone, electronic mail, or other forms of correspondence. Kharazmi shall perform
the services as Chairman pursuant to this Agreement at NuGene’s offices, located in Irvine, California, only when reasonably
requested by NuGene.

 

    	 	1	 

     

    

 

 

3.4          Loyal and Conscientious Performance.
While serving as Chairman hereunder, Kharazmi will devote no less than one day each week to the performance of his duties, and
will not take any action that would directly or indirectly promote any competitor or impair the interests of NuGene. Subject to
the foregoing, while acting as Chairman, Kharazmi may engage in other business or charitable activities to the extent that they
do not interfere or create a conflict with the fiduciary obligations of the Chairman owed to NuGene. Kharazmi will be free to represent
or perform services for other persons while acting solely as the Chairman. However, Kharazmi agrees that Kharazmi does not presently
perform, and will not perform during the Term, consulting or other services for companies whose businesses are or would be, in
any material way, competitive with NuGene, without the Board’s prior approval.

 

IV

TERM AND TERMINATION

 

4.1          Term.

 

4.1.1.          Initial
Term. The Term of this Agreement shall commence on the 22nd day of September, 2016, and shall continue for a period
of thirty-six (36) months, unless sooner terminated as provided for herein (the “Initial Term”).

 

4.1.1.          Renewal
Term. This Agreement shall remain in full force and effect and shall renew for an additional thirty-six (36) month period
(referred to as a “Renewal Term”), provided that neither Party at least ninety (90) days prior to the end of
Initial Term gives written notice to the other of its intent to have the Agreement not remain in full force and effect for the
Renewal Term.

 

4.1.2.          Term
Defined. For purposes of this Agreement, the word “Term” shall specifically include the Initial Term and the
Renewal Term hereunder.

 

4.2          Resignation
by Kharazmi. Kharazmi may terminate this Agreement and resign from his position as Chairman of the Board at any time,
for any reason or no reason, with or without Cause, by providing the Board 30-days advance written notice. Thereafter, all obligations
of NuGene and Kharazmi under this Agreement shall cease except that Kharazmi will be entitled to all compensation earned through
the effective date of his resignation as well as any separation compensation and benefits provided in Articles V and VI, below,
as applicable.

 

4.3          No
Removal by the Board Without Cause. The Board may remove Kharazmi from his position as Chairman of the Board
only for Cause and for no other reason. Any attempt by the Board to remove Kharazmi as the Chairman for any reason other than Cause
shall be null and void and all obligations of the Parties hereunder shall remain in full force and effect.

 

4.4          Removal
by the Board for Cause. The Board may terminate this Agreement and remove Kharazmi from his position as Chairman
of the Board at any time for Cause upon 30-days prior written notice to Kharazmi explaining the Cause, provided that Kharazmi does
not cease the conduct constituting Cause prior to the expiration of such thirty 30-day period. Thereafter, all obligations of NuGene
and Kharazmi under this Agreement shall cease except that Kharazmi will be entitled to all compensation earned through the effective
date of his removal for Cause as well as any separation compensation and benefits provided in Articles V and VI, below, as applicable.

 

4.5          Removal
Due to Death or Complete Disability. If Kharazmi dies or suffers a Complete Disability (as defined below) during
the Term, Chairman’s service as Chairman of the Board shall automatically terminate upon such death or Complete Disability.
Thereafter, all obligations of NuGene under this Agreement shall cease except that Chairman or Chairman’s heirs will be entitled
to all compensation earned through the effective date of resignation as well as any separation compensation and benefits provided
in Articles V and VI, below, as applicable.

 

    	 	2	 

     

    

  

4.6          Definitions. For
purposes of this Agreement, the following terms shall have the following meanings:

 

4.6.1.           Cause. “Cause”
shall mean that one or more of the following has occurred: (i) Kharazmi has been convicted for, or entered a plea of guilty
or nolo contendere to, a felony crime involving fraud, dishonesty, or violence (under the laws of the United States or any relevant
state, in the circumstances, thereof); (ii) Kharazmi has intentionally or willfully engaged in material acts of fraud, dishonesty,
or gross misconduct that have a material adverse effect on NuGene; (iii) the willful failure or refusal of Kharazmi to carry
out the lawful directions of the Board (determined by a majority of the then serving directors other than Kharazmi) or the duties
assigned to Kharazmi by the Board, which are not otherwise inconsistent with this Agreement; (iv) any material violation by
Kharazmi of any written policy applicable to Kharazmi; or, (v) any material breach by Kharazmi of any provision of this Agreement
or any other Agreement between NuGene and Kharazmi. However, notwithstanding the foregoing, the termination of Kharazmi’s
services as Chairman shall be subject to the 30-day period referenced in Section 4.4, above, to correct the breach or failure or
refusal. During this 30-day notice period, Kharazmi will be afforded the opportunity to make a presentation to the Board regarding
the matters referred to in the notice.

 

4.6.2.          Complete
Disability. “Complete Disability” shall mean the inability of Kharazmi to perform his duties under
this Agreement because Kharazmi has become permanently disabled within the meaning of any policy of disability income insurance
covering employees of NuGene then in force. In the event NuGene has no policy of disability income insurance covering employees
of NuGene in force when Kharazmi becomes disabled, the term Complete Disability shall mean the inability of Kharazmi to perform
his duties under this Agreement by reason of any incapacity, physical or mental, which the Board (based on a majority vote of the
directors then serving other than Kharazmi), based upon medical advice or an opinion provided by a licensed physician acceptable
to the Board, determines to have incapacitated Kharazmi from satisfactorily performing Kharazmi’s usual services for NuGene
for a period of at least one hundred twenty (120) consecutive days during any 12-month period.

 

V

COMPENSATION

 

5.1          Base
Compensation. During and throughout the Term NuGene shall pay Kharazmi Ten Thousand Dollars ($10,000) per month (the “Base
Compensation”), payable in accordance with NuGene’s policy for payments to its employees.

 

5.2          Annual
Discretionary Bonuses. In addition to the Base Compensation, Kharazmi will be eligible to receive annual and periodic
bonuses in such amounts and upon such terms as may be determined from time to time by the Board.

 

5.3          Reductions
to Base Compensation. The Base Compensation may be reduced only by mutual written agreement of Kharazmi and NuGene.

 

5.4          Withholding
Taxes. It is the express intent of the Parties, and Kharazmi understands and agrees, that Kharazmi is an independent
contractor and not an employee of NuGene. As a result, NuGene will not make deductions for taxes from any amounts payable to Chairman
as a result of his services to NuGene or as a result of the vesting or settlement of any equity-based awards (except as otherwise
required by applicable law or regulation). Any taxes imposed on Kharazmi due to his services to NuGene (including upon the issuance,
vesting and settlement of any equity-based awards) will be the sole responsibility of Kharazmi.

 

5.5          Stock
Awards.

 

5.5.1.          Restricted
Stock Unit Grant. As an inducement to Kharazmi’s agreement to serve as Chairman of the Board, Kharazmi will be granted
an award consisting of two million (2,000,000) Restricted Stock Units. The terms and conditions for the Restricted Stock Units
are contained in the Restricted Stock Units Agreement executed concurrently with this Agreement.

 

    	 	3	 

     

    

 

5.5.2.          Warrants.
As a further inducement to Kharazmi’s agreement to serve as Chairman of the Board, Kharazmi will be granted Warrants to acquire
the common stock of NuGene. The terms and conditions for the Warrants are contained in the Warrant Agreement executed concurrently
with this Agreement.

 

5.5.3.          Additional
Stock Awards. In addition, NuGene may grant Kharazmi additional stock awards at such times and on such terms
as may be decided from time to time by the Board or its Compensation Committee, in its sole discretion.

 

5.5.4.          Stock
Issuance Bonus. Immediately upon execution of this Agreement NuGene shall issue to Kharazmi two million (2,000,000) shares
of common stock of NuGene. The shares will be restricted shares, and upon receipt by Kharazmi, the shares shall be free and clear
of all liens and encumbrances, and Kharazmi shall have full ownership of the shares.

 

5.6          Expenses.

 

5.6.1.          Ordinary
Business Expenses. Kharazmi is authorized to incur reasonable expenses in the conduct of his services to NuGene as
Chairman, including expenses for meals, travel, and other similar items. NuGene shall prepay or reimburse Kharazmi for all such
expenses.

 

5.6.2.          Expense
Prepayment and Reimbursement Procedures. All prepayments and reimbursements of Kharazmi’s expenses pursuant
to this Section 5.6 are subject to Kharazmi’s provision of invoices, an itemized accounting, or other appropriate documentation
evidencing such expenses no later than three (3) months following the date such expenses were incurred. Any reimbursement
payment shall be made by NuGene as soon as practicable following its receipt of such documentation, but in no event later than
the end of Kharazmi’s taxable year following the year in which Kharazmi incurred such expenses.

 

5.7          Indemnification. NuGene
shall indemnify Kharazmi to the fullest extent permitted by NuGene’s Bylaws and applicable Delaware law. The Parties further
agree that all liabilities incurred by Kharazmi in his capacity as Chairman shall be incurred for the account of NuGene, and Kharazmi
shall not be personally liable therefore. Kharazmi shall not be liable to NuGene, or any of its respective subsidiaries, affiliates,
employees, officers, directors, agents, representatives, successors, assigns, stockholders, and their respective subsidiaries and
affiliates, and NuGene shall, and hereby agrees to, indemnify, defend and hold Kharazmi harmless from and against any and all damages
and/or loss or liability (including, without limitation, all cost of defense thereof), for any acts or omissions in the performance
of service under and within the scope of this Agreement on the part of Kharazmi, other than for acts which are deemed to be grossly
negligent or criminal in nature.

 

5.8          Insurance. As
soon as practicable, NuGene shall maintain an insurance policy or policies providing officers and directors’ liability insurance
and shall include Kharazmi as an insured under the officers and directors liability insurance policy, with coverage to be in an
amount determined by the Board. Said coverage shall also specifically encompass all prior acts regarding NuGene and shall provide
coverage to Kharazmi after termination of this Agreement for all time periods prior to termination of the Agreement. This Section
5.8 shall expressly survive the termination of this Agreement.

 

    	 	4	 

     

    

  

VI

CHANGE OF CONTROL TERMINATION BENEFITS

 

6.1          Change
of Control Benefits. In the event that within twelve (12) months following a Change of Control either: (i) Kharazmi
is removed from his position as Chairman of the Board without Cause; or, (ii)  Kharazmi resigns as the Chairman, then NuGene
shall provide Kharazmi with a single lump sum payment equal to the greater of (i) the amount of Base Compensation remaining over
the remainder of the Term (limited to the Initial Term or the Renewal Term, as applicable); or, two hundred percent (200%) of
the annual Base Compensation then in effect, to be paid within thirty (30) days after the Change in Control.

 

6.2          Change
of Control Defined. “Change of Control” means the occurrence of any of the following events: (i) the
closing of the sale, transfer or other disposition of all or substantially all of NuGene’s assets or the exclusive license
of substantially all of the intellectual property of NuGene material to the business of NuGene resulting in NuGene being unable
to continue its business as in effect prior to such license; provided, however, that a mortgage, pledge or grant of a security
interest to a bona fide lender shall not by itself constitute a Change of Control; (ii) the consummation of a merger or consolidation
of NuGene with or into another entity in which the stockholders of NuGene exchange their shares of capital stock of NuGene for
cash, stock, property, or other consideration (except one in which the stockholders of NuGene as constituted immediately prior
to such transaction continue to hold after the transaction at least 50% of the voting power of the capital stock of NuGene or the
surviving or acquiring entity or parent entity of the surviving or acquiring entity); (iii) any “person,” as such
term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder
(the “Exchange Act”) (other than (a) a trustee or other fiduciary holding securities under an employee benefit
plan of NuGene, (b) a corporation owned, directly or indirectly, by the stockholders of NuGene in substantially the same proportions
as their ownership of stock of NuGene or (c) any current beneficial stockholder or group, as defined by Rule 13d-5 of the
Exchange Act, including the heirs, assigns and successors thereof, of beneficial ownership, within the meaning of Rule 13d 3 of
the Exchange Act, of securities possessing more than 20% of the total combined voting power of NuGene’s outstanding securities)
hereafter becomes the “beneficial owner,” as defined in Rule 13d 3 of the Exchange Act, directly or indirectly, of
securities of NuGene representing 35% or more of the total combined voting power represented by NuGene’s then outstanding
voting securities; or, (iv) individuals who, as of sixty (60) days after the Effective Date of this Agreement are members
of the Board (the “Incumbent Board”) cease for any reason to constitute at least a majority of the members of
the Board; provided, however, that if the appointment or election (or nomination for election) of any new Board member was approved
or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member shall, for purposes
of this Agreement, be considered as a member of the Incumbent Board; provided further, however, that a transaction under clauses
(ii) or (iii) above shall not constitute a Change of Control: (A) if its primary purpose is to change the state
of NuGene’s incorporation, (B) if its primary purpose is to create a holding company that will be owned in substantially
the same proportions by the persons who held NuGene’s securities immediately prior to such transaction, or (C) if it
is a bona fide equity financing in which NuGene is the surviving corporation.

 

VII

TAX TREATMENT

 

7.1          Certain
Payments. Notwithstanding anything contained in this Agreement to the contrary, to the extent that any payment or benefit
(within the meaning of Section 280G(b)(2) of the Code) to Kharazmi or for Kharazmi’s benefit, paid or payable or distributed
or distributable pursuant to the terms of this Agreement or otherwise in connection with, or arising out of, Kharazmi’s services
to NuGene or a Change of Control (a “Payment” or “Payments”), would be subject to the excise tax
imposed under Code Section 4999, or any interest or penalties are incurred by Kharazmi with respect to such excise tax (such
excise tax, together with any such interest and penalties, are hereinafter collectively referred to as the “Excise Tax”),
the Payments shall be reduced (but not below zero) if and to the extent that a reduction in the Payments would result in Kharazmi
retaining a larger amount, on an after-tax basis (taking into account federal, state and local income taxes and the Excise Tax),
than if Kharazmi received all of the Payments (any such reduced amount is hereinafter referred to as the “Limited Payment
Amount”). NuGene shall reduce or eliminate the Payments by (i) first reducing or eliminating those payments which
are payable in cash; and, then (ii) by reducing or eliminating acceleration of stock options, in reverse order beginning with
the options that but for the acceleration would have vested the farthest in time from the Determination (as defined below).

 

    	 	5	 

     

    

  

7.2          Determination.
An initial determination as to whether the Payments shall be reduced to the Limited Payment Amount and the amount of such Limited
Payment Amount shall be made, at NuGene’s expense, by the accounting firm that is NuGene’s independent accounting firm
as of the date of the Change of Control (the “Accounting Firm”). The Accounting Firm shall provide its determination
(the “Determination”), together with detailed supporting calculations and documentation, to NuGene and Kharazmi
within five (5) days of the termination date, if applicable, or such other time as requested by NuGene or by Kharazmi (provided
Kharazmi reasonably believes that any of the Payments may be subject to the Excise Tax) and, if the Accounting Firm determines
that no Excise Tax is payable by Kharazmi with respect to a Payment or Payments, it shall furnish Kharazmi with an opinion reasonably
acceptable to Kharazmi that no Excise Tax will be imposed with respect to any such Payment or Payments. Within ten (10) days
of the delivery of the Determination to Kharazmi, Kharazmi shall have the right to dispute the Determination (the “Dispute”).
If there is no Dispute, the Determination shall be binding, final and conclusive upon NuGene and Kharazmi, subject to the application
of Section 7.3 below.

 

7.3          Excess
Payments and Underpayments. As a result of the uncertainty in the application of Sections 4999 and 280G of the Code, it
is possible that the Payments actually made to, or provided for the benefit of, Kharazmi either will be greater (an “Excess
Payment”) or less (an “Underpayment”) than the proper Limited Payment Amount provided for in Section 7.1,
above.

 

7.3.1.          Excess
Payment. If it is established, pursuant to a final and conclusive determination of a court or the Internal
Revenue Service (the “IRS”) that an Excess Payment has been made, Kharazmi must repay such Excess Payment to
NuGene; provided, that no Excess Payment will be repaid by Kharazmi to NuGene unless, and only to the extent that, the repayment
would either reduce the amount on which Kharazmi is subject to tax under Code Section 4999 or generate a refund of tax imposed
under Code Section 4999.

 

7.3.2.          Underpayment.
In the event that it is determined by (i) the Accounting Firm, NuGene (which shall include the position taken by NuGene, or
together with its consolidated group, on its federal income tax return) or the IRS, or (ii) pursuant to a determination by
a court, or (iii) upon the resolution to Kharazmi’s satisfaction of the Dispute, that an Underpayment has occurred,
NuGene shall pay an amount equal to the Underpayment to Kharazmi within ten (10) days of such determination or resolution,
together with interest on such amount at the applicable federal rate under Code Section 7872(f)(2) from the date such amount
would have been paid to Kharazmi until the date of payment.

 

7.4          Code Section 409A.

 

7.4.1.          Severance
Benefits. Notwithstanding anything to the contrary set forth herein, any payments and benefits provided under this Agreement
(the “Severance Benefits”) that constitute “deferred compensation” within the meaning of Section 409A
of the Code and the regulations and other guidance thereunder or any state law of similar effect (collectively “Section
409A”) and that are not exempt from Section 409A shall not commence in connection with Kharazmi’s termination
of employment unless and until Kharazmi has also incurred a “separation from service” (as such term is defined in Treasury
Regulation Section 1.409A-1(h) (“Separation From Service”). For purposes of Section 409A, each payment
provided in Article VI, above, will be treated as a separate payment.

 

7.4.2.          Exemptions.
For the avoidance of doubt, it is intended that payments of the Severance Benefits set forth in this Agreement satisfy, to the
greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulation Sections
1.409A-1(b)(4) [short-term deferral], 1.409A-1(b)(5) [stock options] and 1.409A-1(b)(9) [separation pay]. However, if NuGene (or,
if applicable, the successor entity thereto) determines that a Severance Benefit constitutes “deferred compensation”
under Section 409A and Kharazmi is, on Kharazmi’s Separation From Service, a “specified employee” of NuGene
or any successor entity thereto, as such term is defined in Section 409A(a)(2)(B)(i) of the Code and the Treasury regulations,
then, solely to the extent necessary to avoid the incurrence of the adverse personal tax consequences under Section 409A,
the timing of the Severance Benefit payment shall be delayed until the earlier to occur of: (i) the date that is six months
and one day after Kharazmi’s Separation From Service; or (ii) the date of Kharazmi’s death (such applicable date,
the “Specified Employee Initial Payment Date”). On the Specified Employee Initial Payment Date, NuGene (or the
successor entity thereto, as applicable) shall pay to Kharazmi a lump sum amount equal to the Severance Benefit payment that Kharazmi
would otherwise have received through the Specified Employee Initial Payment Date if the payment of the Severance Benefits had
not been so delayed pursuant to this Section. The Severance Benefits are intended to qualify for an exemption from application
of Section 409A or to comply with its requirements to the extent necessary to avoid adverse personal tax consequences under
Section 409A, and this Agreement shall be interpreted accordingly.

 

    	 	6	 

     

    

  

VIII

CONFIDENTIAL INFORMATION AND RELATED
COVENANTS

 

8.1          Trade
Secrets Covenants. Kharazmi shall not at any time, whether during or subsequent to the Term, unless specifically consented
to in writing by NuGene, either directly or indirectly use, divulge, disclose or communicate to any person, firm, or corporation,
in any manner whatsoever, any confidential information concerning any matters affecting or relating to the business of NuGene,
including, but not limited to, the names, buying habits, or practices of any of its customers, its’ marketing methods and
related data, the names of any of its vendors or suppliers, costs of materials, the prices it obtains or has obtained or at which
it sells or has sold its products or services, manufacturing and sales, costs, lists or other written records used in NuGene’s
business, compensation paid to employees and other terms of employment, or any other confidential information of, about or concerning
the business of NuGene, its manner of operation, or other confidential data of any kind, nature, or description. The Parties hereby
stipulate that as between them, the foregoing matters are important, material, and confidential trade secrets and affect the successful
conduct of NuGene’s business and its goodwill, and that any breach of any term of this Section 8.1 is a material breach of
this Agreement.

 

8.2          Customer
Accounts Covenants. As used herein, the term “Customer Accounts” shall mean all accounts, clients, customers,
and the like of NuGene and its affiliates, subsidiaries, licensees, and business associations, whether now existing or hereafter
developed or acquired, including any and all accounts developed or acquired by or through the efforts of Kharazmi. During and through
the Term and continuing for a period of thirty-six (36) months immediately following the termination of Kharazmi as Chairman, Kharazmi
shall not directly or indirectly make known to any person, firm, corporation or entity the names or addresses of any of the Customer
Accounts or any other information pertaining to them. During this same time period, Kharazmi shall not, directly or indirectly,
for Kharazmi or any other person, firm, corporation or entity, divert, take away, call on or solicit, or attempt to divert, take
away, call on or solicit, any of the Customer Accounts, including but not limited to those Customer Accounts which Kharazmi called
or with whom Kharazmi became acquainted during Kharazmi’s tenure as Chairman.

 

8.3          Employees
Covenant. During and through the Term of this Agreement and continuing for a period of thirty-six (36) months immediately
following the termination of Kharazmi’s tenure as Chairman, Kharazmi shall not, directly or indirectly, cause or induce,
or attempt to cause or induce, any employee of NuGene to terminate his or her employment with NuGene, as such employment exists
at any time following the execution of this Agreement.

 

8.4          Books
and Records. All equipment, notebooks, documents, memoranda, reports, files, samples, books, correspondence, lists, computer
disks and data bases, computer programs and reports, computer software, and all other written, graphic and computer generated or
stored records affecting or relating to the business of NuGene which Kharazmi shall prepare, use, construct, observe, possess,
or control shall be and remain the sole and exclusive property of NuGene, and shall constitute trade secret information of NuGene.
Within five (5) days of the termination of Kharazmi as Chairman, Kharazmi shall promptly deliver to NuGene all such equipment,
notebooks, documents, memoranda, reports, files, samples, books, correspondence, lists, computer disks and data bases, computer
programs and reports, computer software, and all other written, graphic and computer generated or stored records relating to the
business of NuGene which are or have been in the possession or under the control of Kharazmi.

 

    	 	7	 

     

    

  

8.5          Advertising
Waiver. During the Term Kharazmi agrees to permit NuGene and/or its affiliates, and persons or other organizations authorized
by the NuGene and/or its affiliates, to use, publish, and distribute advertising or sales promotional literature concerning the
products and/or services of NuGene and/or its affiliates, or the machinery and equipment used in the provision thereof, in which
Kharazmi’s name and/or pictures of Kharazmi taken in the course of Kharazmi’s provision of services to the NuGene and/or
its affiliates, appear. Kharazmi hereby waives and releases any claim or right Kharazmi may otherwise have arising out of such
use, publication, or distribution.

 

8.6          Injunctive
Relief. Kharazmi acknowledges that if Kharazmi violates any of the provisions of this Article VIII, it will be difficult
to determine the amount of damages resulting to NuGene. In addition to any other remedies which it may have, NuGene shall also
be entitled to temporary and permanent injunctive relief without the necessity of proving actual damages.

 

8.7          Enforcement
of Covenants. It is the desire and intent of the Parties that the provisions of this Article VIII shall be enforced to
the fullest extent permissible under the laws and public policies applied in each jurisdiction in which enforcement is sought.
Accordingly, if any particular portion of this Article VIII shall be adjudicated to be invalid or unenforceable, this Article VIII
shall be deemed amended to delete therefrom the portion thus adjudicated to be invalid or unenforceable, such deletion to apply
only with respect to the operation of this Article in the particular jurisdiction in which such adjudication is made.

 

IX

ADDITIONAL PROVISIONS

 

9.1          Executed
Counterparts. This Agreement may be executed in any number of counterparts, all of which when taken together shall be considered
one and the same agreement, it being understood that all Parties need not sign the same counterpart. In the event that any signature
is delivered by Fax or by E-Mail, such signature shall create a valid and binding obligation of that Party (or on whose behalf
such signature is executed) with the same force and effect as an original thereof. Any photographic, photocopy, or similar reproduction
copy of this Agreement, with all signatures reproduced on one or more sets of signature pages, shall be considered for all purposes
as if it were an executed counterpart of this Agreement.

 

9.2          Entire
Agreement. This Agreement, and all references, documents, or instruments referred to herein, contains the entire agreement
and understanding of the Parties in respect to the subject matter contained herein. The Parties have expressly not relied upon
any promises, representations, warranties, agreements, covenants, or undertakings, other than those expressly set forth or referred
to herein. This Agreement supersedes (i) any and all prior written or oral agreements, understandings, and negotiations between
the Parties with respect to the subject matter contained herein; and, (ii) any course of performance and/or usage of the trade
inconsistent with any of the terms hereof.

 

9.3          Severability.
Each and every provision of this Agreement is severable and independent of any other term or provision of this Agreement. If any
term or provision hereof is held void or invalid for any reason by a court of competent jurisdiction, such invalidity shall not
affect the remainder of this Agreement.

 

9.4          Governing
Law. This Agreement shall be governed by the laws of the State of California, without giving effect to any choice or conflict
of law provision or rule (whether of the State of California or any other jurisdiction) that would cause the application of the
laws of any jurisdiction other than the State of California. If any court action is necessary to enforce the terms and conditions
of this Agreement, the Parties hereby agree that the Superior Court of California, County of Orange, shall be the sole jurisdiction
and venue for the bringing of such action.

 

    	 	8	 

     

    

  

9.5          Enforcement.
The Parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed
in accordance with their specific terms or were otherwise breached. Accordingly, it is agreed that the Parties shall be entitled
to seek an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions
of this Agreement, this being in addition to any other remedy to which they are entitled at law or in equity. The remedies of the
Parties under this Agreement are cumulative and shall not exclude any other remedies to which any person may be lawfully entitled.

 

9.6          Waiver.
No failure by any Party to insist on the strict performance of any covenant, duty, agreement, or condition of this Agreement or
to exercise any right or remedy on a breach shall constitute a waiver of any such breach or of any other covenant, duty, agreement,
or condition.

 

9.7           Recovery
of Fees by Prevailing Party. In the event of any legal action (including arbitration) to enforce or interpret the provisions
of this Agreement, the non-prevailing Party shall pay the reasonable attorneys’ fees and other costs and expenses including
expert witness fees of the prevailing Party in such amount as the court shall determine. In addition, such non-prevailing Party
shall pay reasonable attorneys’ fees incurred by the prevailing Party in enforcing, or on appeal from, a judgment in favor
of the prevailing Party. The preceding sentence is intended by the Parties to be severable from the other provisions of this Agreement
and to survive and not be merged into such judgment.

 

9.8          Recitals.
The facts recited in Article II, above, are hereby conclusively presumed to be true as between and affecting the Parties.

 

9.9          Amendment.
This Agreement may be amended or modified only by a writing signed by all Parties.

 

9.10        Assignment and Binding Effect.
This Agreement shall be binding upon and inure to the benefit of Kharazmi and Kharazmi’s heirs, executors, personal representatives,
assigns, administrators and legal representatives. Because of the unique and personal nature of Kharazmi’s duties under this
Agreement, neither this Agreement nor any rights or obligations under this Agreement shall be assignable by Kharazmi. This Agreement
shall be binding upon and inure to the benefit of NuGene and its successors, assigns and legal representatives. As a condition
to entering into an acquisition agreement, NuGene will require any acquiror or successor to assume its obligations under this Agreement.

 

9.11        Provision
Not Construed Against Party Drafting Agreement. This Agreement is the result of negotiations by and between the Parties,
and each Party has had the opportunity to be represented by independent legal counsel of its choice. This Agreement is the product
of the work and efforts of all Parties, and shall be deemed to have been drafted by all Parties. In the event of a dispute, no
Party shall be entitled to claim that any provision should be construed against any other Party by reason of the fact that it was
drafted by one particular Party.

 

9.12        Agreement
Provisions, Exhibits, and Schedules. When a reference is made in this Agreement to an Article, Section, Subsection, Exhibit,
or Schedule, such reference shall be to said item of this Agreement unless otherwise indicated. The Exhibits and Schedules identified
in this Agreement are incorporated herein by reference and made a part hereof as if set out in full herein.

 

9.13        Consents,
Approvals, and Discretion. Except as herein expressly provided to the contrary, whenever this Agreement requires consent
or approval to be given by a Party, or a Party must or may exercise discretion, the Parties agree that such consent or approval
shall not be unreasonably withheld, conditioned, or delayed, and such discretion shall be reasonably exercised. Except as otherwise
provided herein, if no response to a consent or request for approval is provided within ten (10) days from the receipt of the request,
then the consent or approval shall be presumed to have been given.

 

    	 	9	 

     

    

  

9.14        Further
Assurances. Each Party agrees (i) to furnish upon request to each other Party such further information; (ii) to
execute and deliver to each other Party such other documents; and, (iii) to do such other acts and things, all as another Party
may reasonably request for the purpose of carrying out the intent of this Agreement and the transactions envisioned hereunder.
However, this provision shall not require that any additional representations or warranties be made and no Party shall be
required to incur any material expense or potential exposure to legal liability pursuant to this Section 9.14.

 

9.15        Notices.

 

9.15.1.          Method
and Delivery. All notices, requests and demands hereunder shall be in writing and delivered by hand, by Electronic Transmission,
by mail, or by recognized commercial over-night delivery service (such as Federal Express or UPS), and shall be deemed given (a)
if by hand delivery, upon such delivery; (b) if by Electronic Transmission, upon telephone confirmation of receipt of same; (c)
if by mail, forty-eight (48) hours after deposit in the United States mail, first class, registered or certified mail, postage
prepaid; or, (d) if by recognized commercial over-night delivery service, upon such delivery.

 

9.15.2.          Consent
to Electronic Transmission. Each Party hereby expressly consents to the use of Electronic Transmission for communications
and notices under this Agreement. For purposes of this Agreement, “Electronic Transmission” means a communication (i)
delivered by Fax or E-Mail when directed to the Fax number or E-Mail address, respectively, for that recipient on record with the
sending Party; and, (ii) that creates a record that is capable of retention, retrieval, and review, and that may thereafter be
rendered into clearly legible tangible form.

 

9.15.3.          Address
Changes. Any Party may alter the Fax number, E-Mail address, physical address, or postage address to which communications
or copies are to be sent by giving notice of such change of address to the other Parties in accordance with the provisions of this
Section 9.15.

 

9.16        Best
Efforts. Each Party shall cooperate in good faith with the other Parties generally, and in particular, the Parties shall
use and exercise their best efforts, taking all reasonable, ordinary and necessary measures to ensure an orderly and smooth relationship
under this Agreement, and further agree to work together and negotiate in good faith to resolve any differences or problems which
may arise in the future. However, the obligations under this Section 9.16 shall not include any obligation to incur substantial
expense or liability.

 

9.17        Definitional
Provisions. For purposes of this Agreement, (i) those words, names, or terms which are specifically defined herein shall
have the meaning specifically ascribed to them; (ii) wherever from the context it appears appropriate, each term stated either
in the singular or plural shall include the singular and plural; (iii) wherever from the context it appears appropriate, the masculine,
feminine, or neuter gender, shall each include the others; (iv) the words “hereof”, “herein”, “hereunder”,
and words of similar import, when used in this Agreement, shall refer to this Agreement as a whole, and not to any particular provision
of this Agreement; (v) all references to “Dollars” or “$” shall be construed as being United States Dollars;
(vi) the term “including” is not limiting and means “including without limitation”; and, (vii) all references
to all statutes, statutory provisions, regulations, or similar administrative provisions shall be construed as a reference to such
statute, statutory provision, regulation, or similar administrative provision as in force at the date of this Agreement and as
may be subsequently amended.

 

X

EXECUTION

 

IN WITNESS WHEREOF,
this CHAIRMAN AGREEMENT has been duly executed by the Parties in Orange County, California, and shall be effective as of and on
the Effective Date. Each of the undersigned Parties hereby represents and warrants that it (i) has the requisite power and authority
to enter into and carry out the terms and conditions of this Agreement, as well as all transactions contemplated hereunder; and,
(ii) it is duly authorized and empowered to execute and deliver this Agreement.

 

    	 	10	 

     

    

  

	KHARAZMI:	 	NUGENE:
	 	 	 
	 	 	NUGENE INTERNATIONAL, INC.,
	/s/ Ali Kharazmi	 	a Nevada corporation
	ALI KHARAZMI 	 	 	 
	 	 	 	 
	DATED:  22 September 2016	BY:	/s/ M. Saeed Kharazmi
	 	 	NAME:	M. Saeed Kharazmi
	 	 	TITLE:	CFO/Secretary
	 	 	DATED:	22 September 2016

 

    	 	11Exhibit 10.2

 

THIS WARRANT AND THE SHARES
ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES
LAWS OF ANY STATE, AND ARE SUBJECT TO CERTAIN INVESTMENT REPRESENTATIONS, AND MAY NOT BE SOLD, PLEDGED, OFFERED FOR SALE, OR OTHERWISE
TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION UNDER THE ACT AND SUCH APPLICABLE STATE SECURITIES LAWS, OR AN OPINION
OF COUNSEL SATISFACTORY TO NUGENE INTERNATIONAL, INC. THAT SUCH REGISTRATION IS NOT REQUIRED.

 

	WARRANT TO PURCHASE COMMON STOCK

 

		Corporation:	NUGENE
                                         INTERNATIONAL, INC. (“NuGene”)

		Number of Shares:	Determined
in Accordance With Article I, Below

		Class of Stock:	Common

		Initial Exercise Price:	Seventy
One Cents ($0.71) (closing price of NuGene common stock on the Issue Date)

		Issue Date:	22
September 2016

		Expiration Date:	22
 September 2026

 

I

GRANT OF WARRANT AND WARRANT SHARES

 

ALI KHARAZMI, or his
duly designated assignee (“Holder”), is entitled to purchase that number of fully paid and nonassessable shares
of common stock of NuGene (the “Warrant Shares”) determined as follows:

 

During and throughout the first
24-months immediately following the Issue Date (the “Non-Dilute Term”), the Warrant Shares shall be equal to
the greater of (i) one million (1,000,000) shares; or, (ii) two and one-half percent (2.5%) of the issued and outstanding common
shares of NuGene, determined on an as if converted and issued basis. Upon the expiration of the Non-Dilute Term, the Warrant Shares
shall be fixed in accordance with the above formula, and such number of Warrant Shares shall remain at that number up to and until
the Expiration Date.

 

The initial exercise
price per share (the “Warrant Price”) is set forth above, subject to adjustment pursuant to Article III
of this Warrant to Purchase Common Stock (the “Warrant”). This Warrant is issued pursuant to that certain Chairman
Agreement by and between NuGene and Holder (the “Chairman Agreement”). 

 

II

EXERCISE

 

2.1           Method
of Exercise. Holder may exercise this Warrant, in whole or on part, at any time or times on or after the Issue Date and
on or before the Expiration Date by delivery of a duly executed Notice of Exercise Form, attached as Exhibit 2.1, to NuGene at
the principal office of NuGene (or such other office or agency of NuGene as it may designate by notice in writing to the registered
Holder at the address of such Holder appearing on the books of NuGene). Holder shall also deliver to NuGene, within five (5) business
days of the date said Notice of Exercise is delivered to NuGene, payment of the aggregate Warrant Price for the Warrant Shares
purchased (the “Exercise Price”), with payment by wire transfer or cashier’s check, or as cashless exercise
under Section 2.2, below.

 

    	 	1	 

     

    

  

2.2          Cashless
Exercise. This Warrant may also be exercised at such time by means of a “cashless exercise” in which Holder
shall be entitled to receive a certificate for the number of Warrant Shares equal to the quotient obtained by dividing [(A-B)
(X)] by (A), where:

 

		(A) =	the closing
price of NuGene common stock on the Trading Day immediately preceding the date of such election;

 

		(B) =	the Exercise
Price of this Warrant, as adjusted; and

 

		(X) =	the number of Warrant
                                         Shares issuable upon exercise of this Warrant in accordance with the terms of this Warrant
                                         by means of a cash exercise rather than a cashless exercise.

 

Notwithstanding anything herein to the
contrary, on the Expiration Date, this Warrant shall be automatically exercised via cashless exercise pursuant to this Section
2.2.

 

2.3          Mechanics
of Exercise.

 

2.3.1.          Authorization
of Warrant Shares. NuGene covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights
represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant, be duly authorized, validly
issued, fully paid, and nonassessable and free from all taxes, liens, and charges in respect of the issue thereof (other than
taxes in respect of any transfer occurring contemporaneously with such issue).

 

2.3.2.          Delivery
of Certificates Upon Exercise. Certificates for shares purchased hereunder shall be transmitted by the transfer agent
of NuGene to Holder by crediting the account of the Holder’s prime broker with the Depository Trust Company through its
Deposit Withdrawal Agent Commission (“DWAC”) system if NuGene is a participant in such system, and otherwise
by physical delivery to the address specified by Holder in the Notice of Exercise within five (5) business days from the receipt
by NuGene of the Notice of Exercise Form, surrender of this Warrant, and payment of the aggregate Exercise Price or cashless exercise.
This Warrant shall be deemed to have been exercised on the date the Exercise Price is received by NuGene, or delivery of the Notice
of Exercise Form in the case of a cashless exercise. The Warrant Shares shall be deemed to have been issued, and Holder or any
other person so designated to be named therein shall be deemed to have become a holder of record of such shares for all purposes,
as of the date the Warrant has been exercised by payment to NuGene of the Exercise Price (or cashless exercise) and all taxes
required to be paid by the Holder, if any, pursuant to Section 2.3.5., below, prior to the issuance of such shares, have been
paid.

 

2.3.3.          Delivery
of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, NuGene shall, at the time of delivery
of the certificate or certificates representing Warrant Shares, deliver to Holder a new Warrant evidencing the rights of Holder
to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical
with this Warrant.

 

    	 	2	 

     

    

  

2.3.4.          No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which Holder would otherwise be entitled to purchase upon such exercise, NuGene
shall pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price.

 

2.3.5.          Charges,
Taxes, and Expenses. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue
or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall
be paid by NuGene, and such certificates shall be issued in the name of the Holder or in such name or names as may be directed
by Holder. However, that in the event certificates for Warrant Shares are to be issued in a name other than the name of
the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed
by the Holder; and NuGene may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer
tax incidental thereto.

 

2.3.6.          Closing
of Books. NuGene will not close its stockholder books or records in any manner which prevents the timely exercise of this
Warrant, pursuant to the terms hereof.

 

2.4          Replacement
of Warrants. On receipt of evidence reasonably satisfactory to NuGene of the loss, theft, destruction or mutilation of
this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in
form and amount to NuGene or, in the case of mutilation, or surrender and cancellation of this Warrant, NuGene at its expense
shall execute and deliver, in lieu of this Warrant, a new warrant, which new warrant shall in all respects be identical with this
Warrant.

 

2.5          Assumption
of Warrant. Upon the closing of any Acquisition the successor entity shall assume the obligations of this Warrant, and
then this Warrant shall be exercisable for the same securities, cash, and property as would be payable for the Warrant Shares
issuable upon exercise of the unexercised portion of this Warrant as if such Warrants Shares were outstanding on the record date
for the Acquisition and subsequent closing. For the purpose of this Warrant, “Acquisition” means any sale,
license, or other disposition of all or substantially all of the assets (including intellectual property) of NuGene, or any reorganization,
consolidation, or merger of NuGene where the holders of NuGene’s securities before the transaction beneficially own less
than fifty percent (50%) of the outstanding voting securities of the surviving entity after the transaction.

 

2.6          Term.
This Warrant and all rights hereunder shall expire on the 22nd day of September, 2026.

 

III

ADJUSTMENTS TO THE WARRANT SHARES

 

3.1          Stock
Dividends, Splits, Etc. If NuGene (i) declares or pays a dividend on its common stock payable in common stock or other
securities, or (ii) declares a stock split, then upon exercise of this Warrant, the number of Warrant Shares to be acquired hereunder
shall be adjusted to reflect the action taken under this Section 3.1, meaning that Holder shall be treated as if Holder owned
the Warrant Shares of record as of the date the dividend or stock split occurred.

 

    	 	3	 

     

    

 

3.2          Reclassification,
Exchange, or Substitution. Upon any reclassification, exchange, substitution, or other event that results in a change
of the number and/or class of the securities issuable upon exercise or conversion of this Warrant, Holder shall be entitled to
receive, upon exercise or conversion of this Warrant, the number and kind of securities and property that Holder would have received
for the Warrant Shares if this Warrant had been exercised immediately before such reclassification, exchange, substitution, or
other event. NuGene or its successor shall promptly issue to Holder a new Warrant for such new securities or other property. The
new Warrant shall provide for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided
for in this Article II including, without limitation, adjustments to the Warrant Price and to the number of securities or
property issuable upon exercise of the new Warrant. The provisions of this Section 3.2 shall similarly apply to successive
reclassifications, exchanges, substitutions, or other events.

 

3.3          No
Impairment. NuGene shall not, by amendment of its Articles of Incorporation or through a reorganization, transfer of assets,
consolidation, merger, dissolution, issue, or sale of securities or any other voluntary action, avoid or seek to avoid the observance
or performance of any of the terms to be observed or performed under this Warrant by NuGene, but shall at all times in good faith
assist in carrying out all the provisions of this Article III and in taking all such action as may be necessary or appropriate
to protect Holder’s rights under this Article III against impairment.

 

IV

ADDITIONAL COVENANTS AND OBLIGATIONS

 

4.1          Notice
of Certain Events. If NuGene proposes at any time (a) to declare any dividend or distribution upon its common stock,
whether in cash, property, stock, or other securities and whether or not a regular cash dividend; (b) to offer for subscription
pro rata to the holders of any class or series of its stock any additional shares of stock of any class or series or other rights;
(c) to effect any reclassification or recapitalization of common stock; (d) to merge or consolidate with or into any
other corporation, or sell, lease, license, or convey all or substantially all of its assets, or to liquidate, dissolve or wind
up; or (e) offer holders of registration rights the opportunity to participate in an underwritten public offering of the
company’s securities for cash, then, in connection with each such event, NuGene shall give Holder (1) at least five
(5) days prior written notice of the date on which a record will be taken for such dividend, distribution, or subscription rights
(and specifying the date on which the holders of common stock will be entitled thereto) or for determining rights to vote, if
any, in respect of the matters referred to in (a) and (b) above; (2) in the case of the matters referred to in (c) and (d)
above at least five (5) days prior written notice of the date when the same will take place (and specifying the date on which
the holders of common stock will be entitled to exchange their common stock for securities or other property deliverable upon
the occurrence of such event); and (3) in the case of the matter referred to in (e) above, the same notice as is given to
the holders of such registration rights.

 

4.2          Registration.
Holder shall have the right to require NuGene to register the Warrant Shares pursuant to any S-8 registration statement filed
by NuGene.

 

4.3          Transferability.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 4.4, below, this Warrant and
all rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at the principal office of NuGene,
together with a written assignment of this Warrant substantially in the form of Exhibit 4.3, attached hereto, duly executed by
Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon
such surrender and, if required, such payment, NuGene shall execute and deliver a new Warrant or Warrants in the name of the assignee
or assignees and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor
a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. A Warrant,
if properly assigned, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

 

    	 	4	 

     

    

  

4.4          Transfer
Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer
of this Warrant shall not be registered pursuant to an effective registration statement under the Securities Act and under applicable
state securities or blue sky laws, NuGene may require, as a condition of allowing such transfer (i) that the Holder or transferee
of this Warrant, as the case may be, furnish to NuGene a written opinion of counsel (which opinion shall be in form, substance
and scope customary for opinions of counsel in comparable transactions) to the effect that such transfer may be made without registration
under the Securities Act and under applicable state securities or blue sky laws, (ii) that the holder or transferee execute and
deliver to NuGene an investment letter in form and substance acceptable to NuGene and (iii) that the transferee be an “accredited
investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), or (a)(8) promulgated under the Securities Act or a qualified
institutional buyer as defined in Rule 144A(a) under the Securities Act.

 

4.5          No
Rights as Shareholder Until Exercise. This Warrant does not entitle Holder to any voting rights or other rights as a shareholder
of NuGene prior to the exercise hereof. Upon the surrender of this Warrant and the payment of the aggregate Exercise Price (or
by means of a cashless exercise), the Warrant Shares so purchased shall be and be deemed to be issued to such Holder as the record
owner of such shares as of the close of business on the later of the date of such surrender or payment.         

 

4.6          Title
to Warrant. Prior to the Expiration Date and subject to compliance with applicable laws and this Warrant, this Warrant
and all rights hereunder are transferable, in whole or in part, at the office or agency of NuGene by the Holder in person or by
duly authorized attorney, upon surrender of this Warrant together with the Assignment Form annexed hereto properly endorsed. The
transferee shall sign an investment letter in form and substance reasonably satisfactory to NuGene.

 

4.7          Limitation
of Liability. No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant or purchase
Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability of Holder for
the purchase price of any Warrant Shares or as a stockholder of NuGene, whether such liability is asserted by NuGene or by creditors
of NuGene.

 

4.8          Compliance
with Securities Laws on Transfer. This Warrant and the Warrant Shares issuable upon exercise this Warrant (and the securities
issuable, directly or indirectly, upon conversion of the Warrant Shares, if any) may not be transferred or assigned in whole or
in part without compliance with applicable federal and state securities laws by the transferor and the transferee.

 

4.9          Limitation
of Liability. No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant to purchase
Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability of Holder for
the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or
by creditors of the Company.

 

    	 	5	 

     

    

 

V

ADDITIONAL PROVISIONS 

 

The provisions of
Article IX of the Chairman Agreement are hereby incorporated by reference as if set forth in full herein.

 

VI

EXECUTION

 

IN WITNESS WHEREOF,
this WARRANT TO PURCHASE COMMON STOCK has been duly executed by the Parties and shall be effective as of and on the Issue Date.
Each of the undersigned Parties hereby represents and warrants that it (i) has the requisite power and authority to enter into
and carry out the terms and conditions of this Warrant, as well as all transactions contemplated hereunder; and, (ii) it is duly
authorized and empowered to execute and deliver this Warrant.

 

	NUGENE:	 	HOLDER:	 
	 	 	 	 
	NUGENE
    INTERNATIONAL, INC.,	 	 	 
	a
    Nevada corporation	 	/s/
    Ali Kharazmi	 
	 	 	 	ALI
    KHARAZMI	 
	 	 	 	 	 
	BY:
    	/s/
    M. Saeed Kharazmi	 	DATED:  22
    September 2016
	 	 	 	 	 
	NAME:
    M. Saeed Kharazmi	 	 	 
	 	 	 	 
	TITLE:
    CFO/Secretary	 	 	 
	 	 	 	 
	DATED:
    22 September 2016	 	 	 

 

    	 	6	 

     

    

  

EXHIBIT 1.1

NOTICE OF EXERCISE

 

To:NUGENE
INTERNATIONAL, INC.

 

(1)          The
undersigned hereby elects to purchase ________ Warrant Shares of NuGene pursuant to the terms of the attached Warrant, and tenders
herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

(2)          Payment
shall take the form of (check applicable box):

 

 ̈        enclosed
check;

 

 ̈        wire
transfer; or

 

 ̈        cashless
exercise.

 

(3)          Please
issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as is
specified below: ____________________________________________.

 

(4)          The
Warrant Shares shall be delivered to the following address:

 

__________________________________________

__________________________________________

__________________________________________

 

(5)          The
undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as
amended.

 

	 	__________________________
	 	NAME:  _______________________
	 	DATED:  ______________________

 

IF INVESTING ENTITY IS DIFFERENT FROM
HOLDER:

 

	 	Name of Investing Entity:	__________________________________________	 
	 	 	 	 
	 	Form of Entity:	__________________________________________	 
	 	 	 	 
	 	State of Formation/Residency:	__________________________________________	 
	 	 	 	 
	 	EIN/SSN:	__________________________________________	 

 

 

	 	BY:  __________________________
	 	 
	 	NAME:  _______________________
	 	 
	 	TITLE:  _______________________
	 	 
	 	DATED:  ______________________

 

    	 	7	 

     

    

 

 

EXHIBIT 3.3

 

ASSIGNMENT FORM

 

TO ASSIGN THE WARRANT, EXECUTE THIS FORM
AND SUPPLY THE REQUIRED INFORMATION.

DO NOT USE THIS FORM TO EXERCISE THE WARRANT

 

FOR VALUE RECEIVED,
the foregoing Warrant and all rights evidenced thereby are hereby assigned to _______________________________________________,
whose address is ______________________________________________________________________________.

 

	 	BY:  __________________________
	 	 
	 	NAME:  _______________________
	 	 
	 	TITLE:  _______________________
	 	 
	 	DATED: ______________________

 

Signature Guaranteed: ___________________________________________

 

NOTE:  The signature to this Assignment
Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever,
and must be guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative
capacity should file proper evidence of authority to assign the foregoing Warrant.

 

    	 	8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}]]